Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06775730 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants
A Phase 1 study of Healthy Adult Female Participants, sponsored by Shionogi.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06775730: Completed Phase 1 study of Healthy Adult Female Participants, sponsored by Shionogi.
NCT06775730 is a Phase 1 study of Healthy Adult Female Participants that has completed, run by Shionogi. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06775730, a Phase 1 study of Healthy Adult Female Participants, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the potential for drug-drug interactions.
Conditions Studied
Interventions
- DRUG Ensitrelvir
Study Locations (1)
California
- Early Phase Clinical Unit Los Angeles - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 1 |
What the finished NCT06775730 record still lists
NCT06775730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Healthy Adult Female Participants appearing as the primary indexed condition, and to 1 intervention - of which Ensitrelvir is the first listed.
NCT06775730 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06775730 about?
NCT06775730 is a clinical study titled "A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants". The purpose of this study is to examine the potential for drug-drug interactions.
What is the current status of trial NCT06775730?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-12-30. Estimated completion is 2025-04-03.
What conditions does trial NCT06775730 study?
This clinical trial studies the following conditions: Healthy Adult Female Participants.
What interventions are being tested in trial NCT06775730?
The interventions under investigation include: Ensitrelvir (DRUG).
Who is sponsoring clinical trial NCT06775730?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06775730 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Female Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06775730's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI